clenbuterol has been researched along with Disease Models, Animal in 34 studies
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the possible therapeutic effects of clenbuterol on cerebral vasospasm after subarachnoid hemorrhage (SAH) in rats." | 7.77 | The effects of clenbuterol on cerebral vasospasm in an experimental rat model of subarachnoid hemorrhage. ( Acar, F; Benek, B; Cirak, B; Coskun, E; Ozcakar, L; Suzer, T; Tahta, K; Yalcin, N, 2011) |
| "Combinations of memantine with clenbuterol extend the respective therapeutic window and provide synergistic cerebroprotective effects after stroke." | 7.72 | Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. ( Culmsee, C; Junker, V; Kremers, W; Krieglstein, J; Plesnila, N; Thal, S, 2004) |
| " The Optimal dosage was 0." | 5.39 | Dose-effects of aorta-infused clenbuterol on spinal cord ischemia-reperfusion injury in rabbits. ( Chen, B; Chen, L; Huang, S; Li, S; Yao, J; Zhang, Y, 2013) |
| "Clenbuterol treatment improved in vivo LV function measured with echocardiography (LVEF (%): HF 35." | 5.35 | Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. ( Barton, PJ; Felkin, LE; Lee, J; Siedlecka, U; Soppa, GK; Stagg, MA; Terracciano, CM; Yacoub, MH; Youssef, S, 2008) |
| " Genes that are susceptible to astrocytic crosstalk between β₂-adrenergic receptors (stimulated by clenbuterol) and TNF-α were identified by qPCR-macroarray-based gene expression analysis in a human 1321 N1 astrocytoma cell line." | 3.80 | β₂-adrenergic agonists modulate TNF-α induced astrocytic inflammatory gene expression and brain inflammatory cell populations. ( Aerts, JL; De Keyser, J; Demol, F; Gerlo, S; Laureys, G; Spooren, A, 2014) |
| "To investigate the possible therapeutic effects of clenbuterol on cerebral vasospasm after subarachnoid hemorrhage (SAH) in rats." | 3.77 | The effects of clenbuterol on cerebral vasospasm in an experimental rat model of subarachnoid hemorrhage. ( Acar, F; Benek, B; Cirak, B; Coskun, E; Ozcakar, L; Suzer, T; Tahta, K; Yalcin, N, 2011) |
| "Our data reveal that clenbuterol-induced skeletal muscle hypertrophy is unable to mimic the beneficial clinical effects of increased musculature derived through targeted strength training in humans, in a rodent model of MNX-induced OA." | 3.76 | Beta2-adrenergic agonist-induced hypertrophy of the quadriceps skeletal muscle does not modulate disease severity in the rodent meniscectomy model of osteoarthritis. ( Bardsley, R; Doherty, M; Jones, SW; Maciewicz, RA; Parr, T; Tonge, DP, 2010) |
| "Clenbuterol, a compound classified as a beta2-adrenoceptor (AR) agonist, has been employed in combination with left ventricular assist devices (LVADs) to treat patients with severe heart failure." | 3.74 | Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes. ( Arora, M; Harding, SE; Kolettis, T; Lee, J; Siedlecka, U; Soppa, GK; Stagg, MA; Terracciano, CM; Yacoub, MH, 2008) |
| "Combinations of memantine with clenbuterol extend the respective therapeutic window and provide synergistic cerebroprotective effects after stroke." | 3.72 | Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. ( Culmsee, C; Junker, V; Kremers, W; Krieglstein, J; Plesnila, N; Thal, S, 2004) |
| "A possible mechanism by which chronic clenbuterol treatment causes multiple physiological changes in skeletal muscle that leads to reduced insulin resistance in the obese Zucker rat (falfa) was investigated." | 3.71 | Attenuation of insulin resistance by chronic beta2-adrenergic agonist treatment possible muscle specific contributions. ( Castle, A; Ivy, JL; Kuo, CH; Yaspelkis, BB, 2001) |
| "Sepsis is a pathology accompanied by increases in myeloid cells and decreases in lymphoid cells in circulation." | 1.72 | Surgical stress quickly affects the numbers of circulating B-cells and neutrophils in murine septic and aseptic models through a β ( Aibiki, M; Choudhury, ME; Miyaike, R; Nishi, Y; Nishioka, R; Sato, N; Shinnishi, A; Takada, Y; Tanaka, J; Umakoshi, K; Yano, H, 2022) |
| "Clenbuterol has been used to alleviate chronic obstructive pulmonary disease and elicit an anabolic response in muscles." | 1.42 | Negative effect of clenbuterol on physical capacities and neuromuscular control of muscle atrophy in adult rats. ( Bisson, JF; Dernoncourt, V; Lang, G, 2015) |
| "Rett syndrome is a severe childhood onset neurodevelopmental disorder caused by mutations in methyl-CpG-binding protein 2 (MECP2), with known disturbances in catecholamine synthesis." | 1.40 | β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome. ( Crawford, B; Garcia, RI; Haggarty, SJ; Mellios, N; Sharma, J; Sheridan, SD; Sur, M; Woodson, J, 2014) |
| " The Optimal dosage was 0." | 1.39 | Dose-effects of aorta-infused clenbuterol on spinal cord ischemia-reperfusion injury in rabbits. ( Chen, B; Chen, L; Huang, S; Li, S; Yao, J; Zhang, Y, 2013) |
| "Mice with Pompe disease were treated with weekly rhGAA injections (20 mg/kg) and a selective β2-agonist, either albuterol (30 mg/l in drinking water) or low-dose clenbuterol (6 mg/l in drinking water)." | 1.38 | β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. ( Bali, D; Dai, J; Kishnani, PS; Koeberl, DD; Li, S; Thurberg, BL, 2012) |
| "Clenbuterol treatment in MLP(-/-) mice was associated with significant changes in the following circulating factors: tissue inhibitor of metalloproteinase-type 1, leukemia inhibitory factor 1, C-reactive protein, apolipoprotein A1, fibroblast growth factor 2, serum glutamic oxaloacetic transaminase, macrophage-derived chemokine, and monocyte chemoattractant protein-3." | 1.35 | Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy. ( Adhikari, N; Barton, PJ; Birks, EJ; Charles, NJ; Hall, JL; Lee, S; Mariash, A; Miller, LW; Polster, SP; Rider, JE; Smolenski, RT; Stangland, J; Tadros, G; Terracciano, CM; Yacoub, MH, 2009) |
| "Clenbuterol treatment improved in vivo LV function measured with echocardiography (LVEF (%): HF 35." | 1.35 | Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. ( Barton, PJ; Felkin, LE; Lee, J; Siedlecka, U; Soppa, GK; Stagg, MA; Terracciano, CM; Yacoub, MH; Youssef, S, 2008) |
| "Treatment with clenbuterol, a beta(2)-adrenoceptor agonist that can enhance regeneration of motor neuron axons, opposed the development of motor deficits in parallel with a reduced proportion of motor neurons with eccentric nuclei consistent with improved synaptic function." | 1.32 | Clenbuterol retards loss of motor function in motor neuron degeneration mice. ( Etlinger, JD; Peng, H; Zeman, RJ, 2004) |
| "Clenbuterol treatment did not increase the normalized force or power output of diaphragm strips from either mdx or control mice." | 1.31 | Force and power output of diaphragm muscle strips from mdx and control mice after clenbuterol treatment. ( Faulkner, JA; Hinkle, RT; Lynch, GS, 2001) |
| "Clenbuterol treatment significantly increased the relative mass (P<0." | 1.30 | Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol. ( Hayes, A; Williams, DA, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 14 (41.18) | 29.6817 |
| 2010's | 15 (44.12) | 24.3611 |
| 2020's | 4 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Nishioka, R | 1 |
| Nishi, Y | 1 |
| Choudhury, ME | 1 |
| Miyaike, R | 1 |
| Shinnishi, A | 1 |
| Umakoshi, K | 1 |
| Takada, Y | 1 |
| Sato, N | 1 |
| Aibiki, M | 1 |
| Yano, H | 1 |
| Tanaka, J | 1 |
| O'Neill, E | 1 |
| Yssel, JD | 1 |
| McNamara, C | 1 |
| Harkin, A | 1 |
| Emili, M | 1 |
| Stagni, F | 1 |
| Salvalai, ME | 1 |
| Uguagliati, B | 1 |
| Giacomini, A | 1 |
| Albac, C | 1 |
| Potier, MC | 1 |
| Grilli, M | 1 |
| Bartesaghi, R | 1 |
| Guidi, S | 1 |
| Van Calster, J | 1 |
| Verstraeten, S | 1 |
| Van Ginderdeuren, R | 1 |
| Vandewalle, E | 1 |
| Stalmans, I | 1 |
| Stalmans, P | 1 |
| Brown, A | 1 |
| Nabel, A | 1 |
| Oh, W | 1 |
| Etlinger, JD | 2 |
| Zeman, RJ | 2 |
| Chen, B | 1 |
| Zhang, Y | 1 |
| Chen, L | 1 |
| Huang, S | 1 |
| Li, S | 4 |
| Yao, J | 1 |
| Laureys, G | 1 |
| Gerlo, S | 1 |
| Spooren, A | 1 |
| Demol, F | 1 |
| De Keyser, J | 1 |
| Aerts, JL | 1 |
| Lang, G | 1 |
| Dernoncourt, V | 1 |
| Bisson, JF | 1 |
| Mellios, N | 1 |
| Woodson, J | 1 |
| Garcia, RI | 1 |
| Crawford, B | 1 |
| Sharma, J | 1 |
| Sheridan, SD | 1 |
| Haggarty, SJ | 1 |
| Sur, M | 1 |
| Bray, N | 1 |
| Han, SO | 1 |
| Koeberl, DD | 3 |
| Ronzoni, G | 1 |
| Del Arco, A | 1 |
| Mora, F | 1 |
| Segovia, G | 1 |
| Milioto, C | 1 |
| Malena, A | 1 |
| Maino, E | 1 |
| Polanco, MJ | 1 |
| Marchioretti, C | 1 |
| Borgia, D | 1 |
| Pereira, MG | 1 |
| Blaauw, B | 1 |
| Lieberman, AP | 1 |
| Venturini, R | 1 |
| Plebani, M | 1 |
| Sambataro, F | 1 |
| Vergani, L | 1 |
| Pegoraro, E | 1 |
| Sorarù, G | 1 |
| Pennuto, M | 1 |
| Siedlecka, U | 2 |
| Arora, M | 1 |
| Kolettis, T | 1 |
| Soppa, GK | 2 |
| Lee, J | 2 |
| Stagg, MA | 2 |
| Harding, SE | 1 |
| Yacoub, MH | 3 |
| Terracciano, CM | 3 |
| Yu, NN | 1 |
| Wang, XX | 1 |
| Yu, JT | 1 |
| Wang, ND | 1 |
| Lu, RC | 1 |
| Miao, D | 1 |
| Tian, Y | 1 |
| Tan, L | 1 |
| Tonge, DP | 1 |
| Jones, SW | 1 |
| Parr, T | 1 |
| Bardsley, R | 1 |
| Doherty, M | 1 |
| Maciewicz, RA | 1 |
| Rider, JE | 1 |
| Polster, SP | 1 |
| Lee, S | 1 |
| Charles, NJ | 1 |
| Adhikari, N | 1 |
| Mariash, A | 1 |
| Tadros, G | 1 |
| Stangland, J | 1 |
| Smolenski, RT | 1 |
| Barton, PJ | 2 |
| Birks, EJ | 1 |
| Miller, LW | 1 |
| Hall, JL | 1 |
| Luo, X | 1 |
| Sun, B | 1 |
| McVie-Wylie, A | 1 |
| Dai, J | 2 |
| Banugaria, SG | 1 |
| Chen, YT | 1 |
| Bali, DS | 1 |
| Benek, B | 1 |
| Acar, F | 1 |
| Cirak, B | 1 |
| Coskun, E | 1 |
| Ozcakar, L | 1 |
| Yalcin, N | 1 |
| Suzer, T | 1 |
| Tahta, K | 1 |
| Thurberg, BL | 1 |
| Bali, D | 1 |
| Kishnani, PS | 1 |
| Dodd, SL | 1 |
| Koesterer, TJ | 1 |
| Höcht, C | 1 |
| Opezzo, JA | 1 |
| Taira, CA | 1 |
| Culmsee, C | 2 |
| Junker, V | 2 |
| Kremers, W | 2 |
| Thal, S | 2 |
| Plesnila, N | 2 |
| Krieglstein, J | 2 |
| Peng, H | 1 |
| Hinkle, RT | 2 |
| Dolan, E | 1 |
| Cody, DB | 1 |
| Bauer, MB | 1 |
| Isfort, RJ | 1 |
| Bonnet, N | 1 |
| Brunet-Imbault, B | 1 |
| Arlettaz, A | 1 |
| Horcajada, MN | 1 |
| Collomp, K | 1 |
| Benhamou, CL | 1 |
| Courteix, D | 1 |
| Shi, H | 1 |
| Zeng, C | 1 |
| Ricome, A | 1 |
| Hannon, KM | 1 |
| Grant, AL | 1 |
| Gerrard, DE | 1 |
| Maier, S | 1 |
| Schneider, HJ | 1 |
| Felkin, LE | 1 |
| Youssef, S | 1 |
| Hayes, A | 1 |
| Williams, DA | 1 |
| Lynch, GS | 1 |
| Faulkner, JA | 1 |
| Castle, A | 1 |
| Yaspelkis, BB | 1 |
| Kuo, CH | 1 |
| Ivy, JL | 1 |
| Frerichs, O | 1 |
| Fansa, H | 1 |
| Ziems, P | 1 |
| Schneider, W | 1 |
| Keilhoff, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy[NCT01942590] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Clinical Investigation of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease, Whether or Not Receiving Enzyme Replacement Therapy[NCT01859624] | Phase 1 | 8 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy[NCT01885936] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 18
| Intervention | meters (Mean) |
|---|---|
| Clenbuterol | 18.09 |
| Placebo Comparator | 6.878 |
Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 52
| Intervention | meters (Mean) |
|---|---|
| Clenbuterol | 16.42 |
| Placebo Comparator | -18.13 |
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 18
| Intervention | change in FVC measured as % expected (Mean) |
|---|---|
| Clenbuterol | 1.575 |
| Placebo Comparator | 2.825 |
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 52
| Intervention | change in FVC measured as % expected (Mean) |
|---|---|
| Clenbuterol | -5.738 |
| Placebo Comparator | 7.775 |
(NCT01942590)
Timeframe: Baseline, Week 52
| Intervention | mmol/mol CN (Mean) |
|---|---|
| Clenbuterol | -1.1 |
| Placebo Comparator | -1.667 |
The Glc4 biomarker is measured in urine and correlates with muscle glycogen content. It is a noninvasive measurement that serves as a biomarker for Pompe disease. (NCT01942590)
Timeframe: Baseline, Week 18
| Intervention | mmol/mol CN (Mean) |
|---|---|
| Clenbuterol | -1.733 |
| Placebo Comparator | 0.0667 |
Liver toxicity, as defined by a >3x increase in AST or ALT from the respective baseline values and/or an increase in direct, indirect or total bilirubin of >3x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52
| Intervention | participants (Number) |
|---|---|
| Clenbuterol | 0 |
| Placebo Comparator | 0 |
Worsening muscle involvement, as defined by >3x increase in CK from baseline that is >2x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52
| Intervention | participants (Number) |
|---|---|
| Clenbuterol | 1 |
| Placebo Comparator | 0 |
The GSGC is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 4 components: Gait, Climbing Stairs, Gower's Manuever, Arising From a Chair. Lowest score 4 = normal muscle function, highest score 27 = unable to perform motor function tests. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 17 | 15.14 | 13.8 |
| Placebo Comparator | 7.5 | 6.5 | 6.5 |
The Late-Life Function & Disability Instrument (Late-Life FDI) is an evaluative outcome instrument for community-dwelling older adults. Highest score 240 = normal function and no disability, lowest score 0 = low levels of frequency of participating in life tasks. (NCT01942590)
Timeframe: Baseline, Week 18, Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 103.75 | 106.7 | 112.5 |
MEP reflects the strength of the abdominal muscles and other expiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | percentage of MEP (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 40.4 | 40 | 53.9 |
| Placebo Comparator | 62.8 | 83.3 | 49.2 |
MIP is a measurement of inspiratory muscle weakness, including weakness of the diaphragm. MIP is decreased in Pompe disease and reflects weakness of respiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | percentage of MIP (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 56.3 | 47.4 | 68.5 |
| Placebo Comparator | 96.8 | 83.8 | 104.6 |
The QMFT is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 16 motor function tests. Lowest score 0 = unable to perform motor function tests, highest score 64 = normal muscle function. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 35 | 40.6 | 46.5 |
| Placebo Comparator | 53.75 | 54.75 | 56.25 |
All participants who experienced adverse events. (NCT01885936)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Albuterol | 5 |
| Placebo Comparator | 5 |
The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. Assessed by physical therapist. (NCT01885936)
Timeframe: Baseline, Week 6, and Week 52
| Intervention | meters (Mean) | |
|---|---|---|
| Change at 6 Weeks | Change at 52 Weeks | |
| Albuterol | 24.0 | 43.6 |
| Placebo Comparator | 32.0 | 13.6 |
FVC (forced vital capacity) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. (NCT01885936)
Timeframe: Baseline, Week 30, and Week 52
| Intervention | Percent of predicted FVC (Mean) | |
|---|---|---|
| Change at 30 Weeks | Change at 52 Weeks | |
| Albuterol | -0.2 | -1.3 |
| Placebo Comparator | 0.4 | 3.0 |
34 other studies available for clenbuterol and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Surgical stress quickly affects the numbers of circulating B-cells and neutrophils in murine septic and aseptic models through a β
Topics: Adrenergic Agonists; Animals; Clenbuterol; Disease Models, Animal; Male; Mice; Neutrophils; Receptor | 2022 |
Pharmacological targeting of β
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Animals; Anti-Inflammatory Agents | 2020 |
Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Animals, Newborn; Clenbuterol; Dentate Gyrus; Disease | 2020 |
A safety evaluation of the intravitreal use of a beta-2 agonist in rabbit eyes.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Clenbuterol; Disease Models, Animal; Intravitreal Inje | 2014 |
Perfusion imaging of spinal cord contusion: injury-induced blockade and partial reversal by β2-agonist treatment in rats.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Disease Models, Animal; Female; Laminectomy; Motor A | 2014 |
Dose-effects of aorta-infused clenbuterol on spinal cord ischemia-reperfusion injury in rabbits.
Topics: Adrenergic beta-Agonists; Angioplasty, Balloon; Animals; Clenbuterol; Disease Models, Animal; Dose-R | 2013 |
β₂-adrenergic agonists modulate TNF-α induced astrocytic inflammatory gene expression and brain inflammatory cell populations.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Animals, Newborn; Astrocytes; Astrocytoma; Brain; Cell | 2014 |
Negative effect of clenbuterol on physical capacities and neuromuscular control of muscle atrophy in adult rats.
Topics: Analysis of Variance; Animals; Bronchodilator Agents; Clenbuterol; Disease Models, Animal; Explorato | 2015 |
β2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome.
Topics: Adrenergic beta-Antagonists; Animals; Behavior, Animal; Clenbuterol; Disease Models, Animal; Female; | 2014 |
Neurodevelopmental disorders: righting Rett syndrome with IGF1.
Topics: Adrenergic beta-Antagonists; Animals; Clenbuterol; Disease Models, Animal; Female; Humans; Insulin-L | 2014 |
Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
Topics: alpha-Glucosidases; Animals; Clenbuterol; Dehydroepiandrosterone; Dependovirus; Disease Models, Anim | 2016 |
Enhanced noradrenergic activity in the amygdala contributes to hyperarousal in an animal model of PTSD.
Topics: Adrenergic Neurons; Amygdala; Animals; Clenbuterol; Disease Models, Animal; Electroshock; Hippocampu | 2016 |
Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Disease Models, Animal; Humans; Male; Mice; Mice, Tr | 2017 |
Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Animals; Calcium Channels, L-Type; | 2008 |
Blocking beta2-adrenergic receptor attenuates acute stress-induced amyloid beta peptides production.
Topics: Acute Disease; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Ant | 2010 |
Beta2-adrenergic agonist-induced hypertrophy of the quadriceps skeletal muscle does not modulate disease severity in the rodent meniscectomy model of osteoarthritis.
Topics: Adrenergic beta-Agonists; Animals; Body Weight; Clenbuterol; Disease Models, Animal; Hypertrophy; Ma | 2010 |
Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulating factors in a murine model of cardiomyopathy.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Animals; Apolipoprotein A-I; Aspartat | 2009 |
Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
Topics: Adrenergic beta-Agonists; alpha-Glucosidases; Animals; Clenbuterol; Disease Models, Animal; Enzyme R | 2011 |
The effects of clenbuterol on cerebral vasospasm in an experimental rat model of subarachnoid hemorrhage.
Topics: Adrenergic beta-Agonists; Animals; Basilar Artery; Cerebrovascular Circulation; Clenbuterol; Disease | 2011 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; alpha-Glucosidases; Animals; Clenbuterol; Disease Mo | 2012 |
Clenbuterol attenuates muscle atrophy and dysfunction in hindlimb-suspended rats.
Topics: Adrenergic beta-Agonists; Animals; Body Weight; Calcium-Transporting ATPases; Clenbuterol; Disease M | 2002 |
Anterior hypothalamic beta-adrenergic activity in the maintenance of hypertension in aortic coarctated rats.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Anterior Hypothalamic Nucleus; Aorti | 2004 |
Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol.
Topics: Adrenergic beta-Agonists; Animals; Brain Ischemia; Cells, Cultured; Clenbuterol; Disease Models, Ani | 2004 |
Clenbuterol retards loss of motor function in motor neuron degeneration mice.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Diagnostic Techniques, Neurological; Disease Models, | 2004 |
Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Analysis of Variance; Animals; Clenbu | 2005 |
Alteration of trabecular bone under chronic beta2 agonists treatment.
Topics: Adipose Tissue; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Albuterol; Animals; B | 2005 |
Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles.
Topics: Adrenergic beta-Agonists; Animals; Cell Cycle Proteins; Cell Line; Clenbuterol; Disease Models, Anim | 2007 |
Enantio-selective effects of clenbuterol in cultured neurons and astrocytes, and in a mouse model of cerebral ischemia.
Topics: Adrenergic beta-Agonists; Animals; Astrocytes; Blood Glucose; Blood Pressure; Brain Ischemia; Cells, | 2007 |
Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure.
Topics: Actin Cytoskeleton; Action Potentials; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists | 2008 |
Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I. Clenbuterol.
Topics: Administration, Oral; Animals; Clenbuterol; Disease Models, Animal; Heart; Male; Mice; Mice, Mutant | 1998 |
Force and power output of diaphragm muscle strips from mdx and control mice after clenbuterol treatment.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Diaphragm; Disease Models, Animal; Mice; Mice, Inbre | 2001 |
Attenuation of insulin resistance by chronic beta2-adrenergic agonist treatment possible muscle specific contributions.
Topics: 3-O-Methylglucose; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Animals; Biologica | 2001 |
Regeneration of peripheral nerves after clenbuterol treatment in a rat model.
Topics: Animals; Cell Count; Clenbuterol; Disease Models, Animal; Male; Muscle Denervation; Muscle, Skeletal | 2001 |